Inlexzo

News

ImmunityBio bags elusive label extension for Anktiva

The FDA has handed ImmunityBio a key label extension for bladder cancer therapy Anktiva, giving it a leg-up on rival drug Inlexzo from J&J.

News

Yellow balloons with smiling faces drawn on them in black ink

J&J says Inlexzo follow-up 'promising' in bladder cancer

Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.

News

Man looking through red lenses of binoculars

11 high-impact drugs to look out for in 2026

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

News

J&J claims FDA okay for bladder cancer drug TAR-200

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.

ImmunityBio bags elusive label extension for Anktiva

J&J says Inlexzo follow-up 'promising' in bladder cancer

11 high-impact drugs to look out for in 2026

J&J claims FDA okay for bladder cancer drug TAR-200

Patients not just at the table, but creating their own: In c...

Securing your ROI: Turning post-acquisition integration into...

Inlexzo

Editor's Picks